Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4852646
Max Phase: Preclinical
Molecular Formula: C55H70F15N13O17
Molecular Weight: 900.10
Molecule Type: Unknown
Associated Items:
ID: ALA4852646
Max Phase: Preclinical
Molecular Formula: C55H70F15N13O17
Molecular Weight: 900.10
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)NC(=O)[C@H](CCNC(=N)N)NC(=O)[C@@H]1CC(=O)NCCC[C@@H](C(=O)NCCN2CCN(CCCC3CCN(CC(=O)N4c5ccccc5NC(=O)c5ccccc54)CC3)CC2)N1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C45H65N13O7.5C2HF3O2/c1-30(59)51-43(64)35(14-18-50-45(46)47)54-44(65)36-28-39(60)48-17-6-11-34(52-36)42(63)49-19-23-56-26-24-55(25-27-56)20-7-8-31-15-21-57(22-16-31)29-40(61)58-37-12-4-2-9-32(37)41(62)53-33-10-3-5-13-38(33)58;5*3-2(4,5)1(6)7/h2-5,9-10,12-13,31,34-36,52H,6-8,11,14-29H2,1H3,(H,48,60)(H,49,63)(H,53,62)(H,54,65)(H4,46,47,50)(H,51,59,64);5*(H,6,7)/t34-,35-,36-;;;;;/m0...../s1
Standard InChI Key: VDXVZLQXPJDGSZ-QCEVHHGWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 900.10 | Molecular Weight (Monoisotopic): 899.5130 | AlogP: -0.21 | #Rotatable Bonds: 16 |
Polar Surface Area: 266.53 | Molecular Species: BASE | HBA: 12 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 20 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.56 | CX Basic pKa: 12.64 | CX LogP: -2.70 | CX LogD: -5.50 |
Aromatic Rings: 2 | Heavy Atoms: 65 | QED Weighted: 0.08 | Np Likeness Score: -0.45 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):